The beneficial effects of C-peptide on diabetic polyneuropathy

Review of Diabetic Studies

Volumn 6, Issue 3, 2009, Pages 187-202

  Kamiya, Hideki ^a,b   Zhang, Weixian ^a   Sima, Anders A F ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NAGOYA UNIVERSITY   (Japan)

Author keywords

BB Wor rat; C peptide; Diabetic neuropathy; Hyperlipidemia; Inflammation; Nerve growth factor; Neuroregulation; Neurotrophic factors; Type 1 diabetes

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); C PEPTIDE; INSULIN RECEPTOR; NERVE GROWTH FACTOR; NEUROTROPHIC FACTOR; NEUROTROPHIN 3; NITRIC OXIDE; PLACEBO; SOMATOMEDIN C;

APOPTOSIS; CHRONIC PAIN; CLINICAL TRIAL; DIABETIC NEUROPATHY; DRUG MECHANISM; GENE CONTROL; HUMAN; INSULIN DEFICIENCY; INSULIN DEPENDENT DIABETES MELLITUS; MORPHOMETRICS; NERVE FIBER DEGENERATION; NERVE FIBER REGENERATION; NONHUMAN; PERIPHERAL NERVE; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SPINAL GANGLION; SUBSTITUTION THERAPY;

EID: 76149119436     PISSN: 16136071     EISSN: 16140575     Source Type: Journal    
DOI: 10.1900/RDS.2009.6.187     Document Type: Review

References (123)

1. Greene DA, Sima AA, Feldman EL, Stevens MJ. Diabetic neuropathy, In: Porte D Jr, Sherwin RS (eds). Ellenberg and Rifkin Diabetes Mellitus. 5th ed., Appleton & Lange, Stanford, 1997, pp. 1009-1076.
2. Sima AA, Kamiya H. Diabetic neuropathy differs in type 1 and type 2 diabetes. Ann NY Acad Sci 2006. 1084:235-249.
3. Dyck PJ, Davies JL, Wilson DM, Service FJ, Melton LJ 3rd, O'Brien PC. Risk factors for severity of diabetic polyneuropathy: intensive longitudinal assessment of the Rochester Diabetic Neuropathy Study Cohort. Diabetes Care 1999. 22:1479-1486.
4. Sima AA. Heterogeneity of diabetic neuropathy. Front Biosci 2008. 13:4809-4816.
5. Sima AA, Bril V, Nathaniel V, McEwen TA, Brown M, Lattimer SA, Greene DA. Regeneration and repair of myelinated fibers in sural nerve biopsies from patients with diabetic neuropathy treated with an aldose reductase inhibitor. N Eng J Med 1988. 319:548-555.
6. Greene DA, Bril V, Sima AA. The relevance and efficacy of aldose reductase inhibitors in human diabetic neuropathy. In: Ward J, Goto Y, (eds). Diabetic Neuropathy. John Wiley & Sons Ltd, London, 1990, Chapt. 13, pp. 133-142.
7. Ziegler D, Reljanovic M, Meknert H, Gries FA. Alpha lipoic acid in the treatment of diabetic polyneuropathy in Germany, current evidence from clinical trials. Exp Clin Endocrin Diab 1999. 107:531-537.
8. Sima AA, Calvani M, Mehra M, Amato A. Acetyl-L-carnitine improves pain, vibratory perception and nerve morphology in patients with chronic diabetic peripheral neuropathy: an analysis of two randomized, placebo-controlled trials. Diabetes Care 2005. 28:96-101.
9. The Diabetes Control Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Engl J Med 1993. 329:977-986.
10. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. The Lancet 1998. 352:S37-S53.
11. Reichard P, Pihl M, Rosenquist U, Sule J. Complications in IDDM are caused by elevated blood glucose level: The Stockholm Diabetes Intervention Study (SDIS) at 10-year follow-up. Diabetologia 1996. 39:1483-1488.
12. Cheatham B, Kahn R. Insulin action and the insulin signaling network. Endocrin Rev 1995. 16:117-142.
13. Sima AA. New insights into the metabolic and molecular basis for diabetic neuropathy. Cell Mol Life Sci 2003. 60:2445-2464.
14. Pierson CR, Zhang W, Murakawa Y, Sima AAF. Early gene responses of trophic factors differ in nerve regeneration in type 1 and type 2 diabetic neuropathy. J Neuropath Exp Neurol 2002. 61:857-871.
15. Brussee V, Cunningham FA, Zochodne DW. Direct insulin signaling of neurons reverses diabetic neuropathy. Diabetes 2004. 53:1824-1830.
16. Ishii D. Implications of insulin-like growth factors in the pathogenesis of diabetic neuropathy. Brain Res Rev 1995. 20:47-67.
17. Park CR. Cognitive effects of insulin in the central nervous system. Neurosci Biobehav Rev 2001. 25:311-323.
18. Luppi P, Cifarelli V, Tse H, Piganelli J, Trucco M. Human C-peptide antagonizes high glucose-induced endothelial dysfunction through the nuclear factor-kappaB pathway. Diabetologia 2008. 51:1534-1543.
19. Sima AA, Zhang W, Kreipke CW, Rafols JA, Hoffman WH. Inflammation in diabetic encephalopathy is prevented by C-peptide. Rev Diabet Stud 2009. 6:37-42.
20. Wiggins TD, Sullivan KA, Pop-Busui R, Amato A, Sima AAF, Feldman EL. Elevated triglycerides correlate with progression of diabetic neuropathy. Diabetes 2009. 58:1634-1640.
21. Sima AA, Kamiya H. Insulin, C-peptide and diabetic neuropathy. Science Med 2004. 10:308-319.
22. Shafqat J, Melles E, Sigmudsson K, Johansson BL, Ekberg K, Alvelius G, Henriksson M, Johansson J, Wahren J, Jörnvall H. Proinsulin C-peptide elicits disaggregation of insulin resulting in enhanced physiological insulin effects. Cell Mol Life Sci 2006. 63:1805-1811.
23. Meyer JA, Subasinghe W, Sima AAF, Keltner Z, Reid GE, Daleke D, Spence DM. Hyperglycemia-induced phosphatidylserine translocation is associated with zink-activated C-peptide resistance in type 2 diabetic erythrocytes. Mol BioSyst 2009. 5:1157-1162.
24. Medawala W, McCahill P, Giebink A, Meyer J, Ku CJ, Spence DM. A molecular level understanding of zinc activation of C-peptide and its effects on cellular communications in the bloodstream. Rev Diabet Stud 2009. This issue.
25. Grunberger G, Qiang X, Li ZG, Mathews ST, Sbriessa D, Shisheva A, Sima AAF. Molecular basis for the insulinomimetic effects of C-peptide. Diabetologia 2001. 44:1247-1257.
26. Jensen ME, Messina EJ. C-peptide induces a concentration-dependent dilatation of skeletal muscle arterioles only in the presence of insulin. Am J Phys 1999. 276:H1223-H1228.
27. Mordes JP, Bortell R, Groen H, Guberski D, Rossini AA, Greiner DL. Autoimmune diabetes mellitus in the BB-rat. In: Sima AA, Shafrir E (eds.). Animal Models of Diabetes. Harwood Acad Publ, Amsterdam, 2001, pp. 1-42.
28. Sima AA, Zhang W, Xu G, Sugimoto K, Guberski DL, Yorek MA. A comparison of diabetic polyneuropathy in type-2 diabetic BBZDR/Wor-rat and in type 1 diabetic BB/Wor-rat. Diabetologia 2000. 43:786-793.
29. Steiner DF, Cunningham L, Spigelman L, Aben B. Insulin biosynthesis: evidence for a precursor. Science 1967. 157:697-700.
30. Steiner DR, Rubenstein AH. Proinsulin C-peptide - biological activity? Science 1997. 277:531-532.
31. Johansson BL, Borg K, Fernquist-Forbes E, Kernell A, Odergren T, Wahren J. Beneficial effects of C-peptide on incipient nephropathy and neuropathy in patients with type 1 diabetes mellitus. Diabet Med 2000. 17:181-189.
32. Johansson BL, Linde B, Wahren J. Effect of C-peptide on blood flow, capillary diffusion capacity and glucose utilization in the exercising forearms of type 1 (insulindependent) diabetic patients. Diabetologia 1992. 35:1151-1158.
33. Forst T, Kunt T, Pohlmann, Goitom K, Engelbach M, Beyer J, Pfützner A. Biological activity of C-peptide on the skin microcirculation in patients with insulin-dependent diabetes mellitus. J Clin Invest 1998. 101:2036-2041.
34. Rigler R, Pramanik A, Jonasson P, Kratz G, Jansson OT, Nygren PA, Stahl S, Ekberg K, Johansson BL, Uhlen S, Uhlen M, Jörnvall H, Wahren J. Specific binding of the proinsulin C-peptide to human cell membranes. Proc Natl Acad Sci USA 1999. 46:13318-13323.
35. Othomo Y, Aperia A, Sahlgren B, Johansson BL, Wahren J. C-peptide stimulates rat renal tubular Na+, K+-ATPase activity in synergism with neuropeptide Y. Diabetologia 1996. 39:199-205.
36. Grunberger G, Sima AA. The C-peptide signaling. Exp Diab Res 2004. 5:25-36.
37. Li ZG, Qiang X, Sima AA, Grunberger G. C-peptide attenuates protein tyrosine phosphatase activity and enhances glycogen synthesis in L6 myoblasts. Biochem Biophys Res Com 2001. 26:615-619.
38. Zhang W, Yorek M, Pierson CR, Murakawa Y, Breidenbach A, Sima AA. Human C-peptide dose dependently prevents early neuropathy in the BB/Wor-rat. Internatl J Exp Diab Res 2001. 2(3):187-194.
39. Stevens MJ, Zhang W, Li F, Sima AA. C-peptide corrects endoneurial blood flow but not oxidative stress in type 1 BB/Wor-rats. Am J Physiol 2004. 287:E497-E505.
40. Cotter MA, Ekberg K, Wahren J, Cameron NE. Effects of proinsulin C-peptide in experimental diabetic neuropathy: vascular actions and modulation by nitric oxide synthase inhibition. Diabetes 2003. 52:1812-1817.
41. Pierson CR, Zhang W, Sima AA. Proinsulin C-peptide replacement in type 1 diabetic BB/Wor-rats prevents deficits in nerve fiber regeneration. J Neuropath Exp Neurology 2003. 62:765-779.
42. Li ZG, Zhang W, Sima AA. C-peptide enhances insulin-mediated cell growth and protection against high glucose induced apoptosis in SH-SY5Y cells. Diabetes Metab Res Rev 2003. 19:375-385.
43. Sima AA, Li ZG. The effect of C-peptide on cognitive dysfunction and hippocampal apoptosis in type 1 diabetes. Diabetes 2005. 54:1497-1505.
44. Kamiya H, Zhang W, Sima AA. Apoptotic stress is counterbalanced by survival elements preventing programmed cell death of dorsal root ganglions in subacute type 1 diabetic BB/Wor-rats. Diabetes 2005. 54:3288-3295.
45. Sima AA. Diabetic neuropathy in type 1 and type 2 diabetes and the effects of C-peptide. Neurol Sci 2004. 220:133-136.
46. Meyer JA, Froelich JM, Reid GE, Karunarathne WK, Spence DM. Metal activated C-peptide facilitates glucose clearance and release of a nitric acid stimulus via the GLUT-1 transporter. Diabetologia 2008. 51:175-182.
47. Luppi P, Geng X, Cifarelli V, Brain P, Trucco M. C-peptide is internalised in human endothelial and vascular smooth muscle cells via endosomes. Diabetologia 2009. 52:2218-2228.
48. Kisfalvi K, Rey O, Young SH, Sinnett-Smith J, Rozengurt E. Insulin potentiates Ca2+ signaling and phosphatidylinositol 4,5-biophosphate hydrolysis induced by Gq protein-coupled receptor agonists through an mTOR-dependent pathway. Endocrinol 2007. 148:3246-3257.
49. Hall KE, Liu J, Sima AAF, Wiley JW. Impaired inhibitory G protein function contributes to increased calcium currents in rats with diabetic neuropathy. J Neurophysiol 2001. 86(2):760-770.
50. Goldstein BJ, Dudley AL. The rat insulin receptor; primary structure and conservation of tissue-specific alternative messenger RNA splicing. Mol Endocrinol 1990. 4:235-244.
51. Sugimoto K, Murakawa Y, Zhang WX, Xu G, Sima AA. Insulin receptor in rat peripheral nerve: its localization and alternatively spliced isoforms. Diabetes Metab Res Rev 2000. 16(5):354-363.
52. Sugimoto K, Murakawa Y, Sima AA. Expression and localization of insulin receptor in rat dorsal root ganglion and spinal cord. J Peripher Nerv Syst 2002. 7(1):44-53.
53. Ariyasu RG, Nichol JA, Ellisman MH. Localization of sodium/potassium adenosine triphosphate in multiple cell types of the murine nervous system with antibodies raised against the enzyme from kidney. J Neurosci 1985. 5:2581-2596.
54. Kordeli E, Lambert S, Bennett V. AnkyrinG. A new ankyrin gene with neural specific isoforms localized at the axonal initial segment and node of Ranvier. J Biol Chem 1995. 270(5):2352-2359.
55. Magnani P, Cherian PV, Gould G, Greene DA, Sima AA, Brosius FC 3rd. Glucose transporters in rat peripheral nerve: paranodal expression of GLUT1 and GLUT3. Metabolism 1996. 45(12):1466-1473.
56. Cherian PV, Kamijo M, Angelides KJ, Sima AA. Nodal Na+-channel displacement is associated with nerve conduction slowing in the chronically diabetic BB/W-rat. Prevention by an aldose reductase inhibitor. J Diabetes Complications 1996. 10(4):192-200.
57. Sima AA, Zhang W, Li ZG, Murakawa Y, Pierson CR. Molecular alterations underlie nodal and paranodal degeneration in type 1 diabetic neuropathy and are prevented by C-peptide. Diabetes 2004. 53:1556-1563.
58. Kamiya H, Zhang W, Ekberg K, Wahren J, Sima AA. C-peptide reverses nociceptive neuropathy in type 1 diabetic BB/Wor-rat. Diabetes 2006. 55:3581-3587.
59. Kamiya H, Murakawa Y, Zhang W, Sima AA. Un-myelinated fiber sensory neuropathy differs in type 1 and type 2 diabetes. Diabetes Metab Res Rev 2005. 21:448-458.
60. Sima AA, Kamiya H. Is C-peptide replacement the missing link for successful treatment of neurological complications in type 1 diabetes? Curr Drug Targets 2008. 9(1):37-46.
61. Haidet J, Cifarelli V, Trucco M, Luppi P. Anti-inflammatory properties of C-peptide. Rev Diabet Stud 2009. This issue.
62. Nordquist L, Wahren J. C-peptide: the missing link in diabetic nephropathy? Rev Diabet Stud 2009. This issue.
63. Forst T, Hach T, Kunt T, Weber MM, Pfützner A. The Role of C-peptide in the regulation of microvascular blood flow. Rev Diabet Stud 2009. This issue.
64. Sima AA, Zhang W, Muzik O, Kreipke CW, Rafols JA, Hoffman WH. Sequential abnormalities in type 1 diabetic encephalopathy and the effects of C-peptide. Rev Diabet Stud 2009. This issue.
65. Vague P, Coste TC, Jannot MF, Raccah D, Tsimaratos M. C-peptide, Na+, K+-ATPase and diabetes. Exp Diabesity Res 2004. 5(1):37-50.
66. Brismar T, Sima AA. Changes in nodal function in nerve fibres of the spontaneously diabetic BB-Wistar rat. Potential clamp analysis. Acta Physiol Scand 1981. 113:499-506.
67. Sima AA, Brismar T. Reversible diabetic nerve dysfunction. Structural correlates to electrophysiological abnormalities. Ann Neurol 1985. 18:21-29.
68. Greene DA, Lattimer SA, Sima AA. Sorbitol, phosphoinositides and sodium-potassium ATPase in the pathogenesis of diabetic complications. N Engl J Med 1987. 316:599-606.
69. Stevens MJ, Dananberg J, Feldman EL, Lattimer SA, Kamijo M, Thomas TP, Shindo H, Sima AA, Greene DA. The linked roles of nitric oxide, aldose reductase and, (Na+/K+)-ATPase in the slowing of nerve conduction in the streptozotocin diabetic rat. J Clin Invest 1994. 94:853-859.
70. Kutanyra T, Kimura K, Makondo K, Furuya T, Suzuki M, Yoshida T, Saito M. Proinsulin C-peptide increases nitric oxide production by enhancing mitogenactivated protein-kinase-dependent transcription of endothelial nitric oxide synthase in aortic enothelial cells of Wistarrats. Diabetologia 2003. 46:1698-1705.
71. Francis GJ, Martinez JA, Liu WQ, Xu K, Ayer A, Fine J, Tuor UI, Glazner G, Hanson LR, Frey II WH, Toth C. Intranasal insulin prevents cognitive decline, cerebral atrophy and white matter changes in murine type 1 diabetic encephalopathy. Brain 2008. 131:3311-3334.
72. Hills CE, Brunskill NJ. Intracellular signaling by Cpeptide. Exp Diabetes Res 2008. 635158.
73. Xu G, Murakawa Y, Pierson CR, Sima AA. Altered beta-tubulin and neurofilament expression and impaired axonal growth in diabetic nerve regeneration. J Neuropath Exp Neurol 2002. 61:164-175.
74. Kamiya H, Zhang W, Sima AA. C-peptide prevents nociceptive sensory neuropathy in type 1 diabetes. Ann Neurol 2004. 56:827-835.
75. Xu G, Sima AA. Altered immediate early gene expression is impaired in diabetic nerve: implications in regeneration. J Neuropath Exp Neurol 2001. 60(10):972-983.
76. Schmeichel AM, Schmetzer JD, Low PA. Oxidative injury and apoptosis of dorsal root ganglion neurons in chronic experimental diabetic neuropathy. Diabetes 2003. 52:165-171.
77. Russel JW, Sullivan KA, Windebank AJ, Herrman DN, Feldman EL. Neurons undergo apoptosis in animal and cell culture models of diabetes. Neurobiol Dis 1999. 6:347-363.
78. Cheng C, Zochodne DW. Sensory neurons with activated caspase-3 survive long-term experimental diabetes. Diabetes 2003. 52:2363-2371.
79. Sima AA, Zhang WX, Tai J, Tze WJ, Nathaniel V. Diabetic neuropathy in STZ-induced diabetic rat and effect of allogenic islet cell transplantation. Morphometric analysis. Diabetes 1988. 37:1129-1136.
80. Kamiya H, Zhang W, Sima AA. Degeneration of Golgi and neuronal loss in dorsal root ganglia in diabetic BB/Worrats. Diabetologia 2006. 49(11):2763-2774.
81. Terada M, Yasuda H, Kikkawa R. Delayed Wallerian degeneration and increased neurofilament phosphorylation in sciatic nerves of rats with streptozotocin-induced diabetes. J Neurol Sci 1998. 155:23-30.
82. Purves T, Middlemas A, Agthong S, Jude FB, Boulton AJ, Fernyhough P, Tomlinson DR. A role for mitogen-activated protein kinases in the etiology of diabetic neuropathy. FASEB J 2001. 15:2508-2514.
83. Brownlees J, Yates A, Bajaj NP, Davis D, Anderton BH, Leigh PN, Show CR, Miller CC. Phosphorylation of neurofilament heavy chain side-arms by stress activated protein kinase-1b/Jun N-terminal kinase-3. J Cell Sci 2000. 113(Pt 3):401-407.
84. Kamiya H, Zhang W, Sima AA. Dynamic changes of neuroskeletal proteins underlie impaired axonal maturation and progressive degeneration in type 1 diabetes. Exp Diabetes Res 2009. 2009:793281.
85. Sima AA, Zhang WX, Sugimoto K, Henry D, Li ZG, Wahren J, Grunberger G. C-peptide prevents and improves chronic type 1 diabetic neuropathy in the BB/Worrat. Diabetologia 2001. 44:889-897.
86. Gilron I, Flatters SJ. Gabapentin and pregablin for the treatment of neuropathic pain: a review of laboratory and clinical evidence. Pain Res Manag 2006. 11 (Suppl A):16-29.
87. Ramos KM, Jiang Y, Svensson CI, Calcutt NA. Pathogenesis of spinally mediated hyperalgesia in diabetes. Diabetes 2007. 56:1569-1576.
88. Burchiel KJ, Russel LC, Lee RP and Sima AA. Spontaneous activity of primary afferent neurons in diabetic BBWistar rats. A possible mechanism of chronic diabetic pain. Diabetes 1985. 34:1210-1213.
89. Hirade M, Yasuda H, Omatsu-Kanbe M, Kikkawa R, Kitasato H. Tetrodotoxin-resistant sodium channels of dorsal root ganglion neurons are readily activated in diabetic rats. Neuroscience 1999. 90:933-937.
90. Kapur D. Neuropathic pain and diabetes. Diabetes Metab Res Rev 2003. 19:S9-S15.
91. Arendt-Nielsen L, Sonnenborg FA, Andersen OK. Facilitation of the withdrawal reflex by repeated transcutaneous electrical stimulation: an experimental study on central integration in humans. Eur J Appl Physiol 2000. 81:165-173.
92. Bachouja MM. Pathophysiology of neuropathic pain. In: Veves A, Malik RA (eds). Diabetic neuropathy. Cliniccal management. Humana Press, Totowa, NJ, 2007, pp 339-350.
93. Pierson CR, Zhang W, Murakawa Y, Sima AA. Insulin deficiency rather than hyperglycemia account for impaired neurotrophic responses and nerve fiber regeneration in type 1 diabetic neuropathy. J Neuropath Exp Neurology 2003. 62:260-271.
94. Kamijo M, Merry AC, Akdas G, Cherian PV, Sima AA. Nerve fiber regeneration following axotomy in the diabetic BB/W-rat. The effect of ARI-treatment. J Diabetes Complications 1996. 10:183-191.
95. Sima AA, Merry AC, Lightle R. Impaired macrophage recruitment in axotomized diabetic nerve. Exp Clin Endocrin Diab 1997. 105:62-63.
96. Sima AA, Levitan I, Ristic H, Kamijo M. Nerve fiber regeneration in the spontaneously diabetic BB/W-rat. In: Hotta N, Greene DA, Ward JD, Sima AA, Boulton AJ (eds). Diabetic Neuropathy: New Concepts and Insights. Elsevier Science B.V., Amsterdam, 1995, pp 27-36.
97. Ide C. Peripheral nerve regeneration. Neurosci Res 1996. 25:101-121.
98. Ishii DN, Glazner GW, Pu S. Role of insulin-like growth factor in peripheral nerve regeneration. Mol Neurobiol 1997. 14:67-116.
99. Fernyhough P, Mill JF, Roberts JL, Ishii DN. Stabilization of tubulin mRNA's by insulin and insulin-like growth factor-1 during neurite formation. Mol Brain Res 1989. 6:109-120.
100. Verge VN, Tetzlatt W, Bisby MA, Richardson PM. Influence of nerve growth factor on neurofilament gene expression in mature primary sensory neurons. J Neurosci 1990. 10:2018-2025.
101. Fernyhough P, Willars GB, Lindsay RM, Tomlinson DR. Insulin and insulin-like growth factor I enhance regeneration in cultured adult rat sensory neurons. Brain 1993. 607:117-124.
102. Sima AA, Nathaniel V, Bril V, McEwen TA, Greene DA. Histopathological heterogeneity of neuropathy in insulin-dependent and non-insulin-dependent diabetes, and demonstration of axo-glial dysjunction in human diabetic neuropathy. J Clin Invest 1988. 81:349-364.
103. Sima AA, Lattimer SA, Yagihashi S, Greene DA. "Axo-glial dysjunction": a novel structural lesion that accounts for poorly reversible slowing of nerve conduction in the spontaneously diabetic BB-rat. J Clin Invest 1986. 77:474-484.
104. Brismar T, Sima AA, Greene DA. Reversible and irreversible nodal dysfunction in diabetic neuropathy. Ann Neurol 1987. 21:504-507.
105. Sima AA, Cherian PV. Neuropathology of diabetic neuropathy and its correlations with neurophysiology. J Clin Neurosci 1997. 4:359-364.
106. Peles E, Nativ M, Lustig M, Grumet M, Schilling J, Martinez R, Plowman GD, Schlessinger J. Identification of a novel contactin-associated transmembrane receptor with multiple domains implicated in protein-protein interactions. EMBO J 1997. 16:978-988.
107. Ratcliffe CF, Qu V, McCormick KA, Tibbs VC, Dixon JE, Schener T, Catterall WA. A sodium channel signaling complex: modulation by associated receptor protein tyrosine phosphatase beta. Nat Neurosci 2000. 3:437-444.
108. Peles E, Nativ M, Campbell PL, Sakurai T, Martinez R, Lev S, Clary DO, Skilling J, Barnea G, Plowman GD. The carbonic ankydrase domain of receptor tyrosine phosphatase beta is a functional ligand for the axonal recognition molecule contactin. Cell 1995. 82:251-260.
109. Johnson KG, Van Vactor D. Receptor protein tyrosine phosphases in nervous system development. Physiol Rev 2003. 83:1-24.
110. Ekberg K, Brismar T, Johansson BL, Jonsson B, Lindström P, Wahren J. Amelioration of sensory nerve dysfunction by C-peptide in patients with type 1 diabetes. Diabetes 2003. 52:536-541.
111. Ekberg K, Brismar T, Johansson BL, Lindström P, Juntti-Berggren L, Norrby A, Berne C, Arnquist HJ, Bolinder J, Wahren J. C-peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy. Diabetes Care 2007. 30:71-76.
112. Johansson BL, Borg K, Fernquist-Forbes E, Odergren T, Remahl S, Wahren J. C-peptide improves autonomic nerve function in IDDM patients. Diabetologia 1996. 39:687-695.
113. Schmidt RE, Dorsey DA, Beaudet LN, Parvin CA, Zhang W, Sima AA. Experimental rat models of type 1 and type 2 diabetes differ in sympathetic neuronal dystrophy. J Neuropath Exp Neurol 2004. 63:450-460.
114. Sima AA, Kamiya H, Li ZG. Insulin, C-peptide hyperglycemia and central nervous system complications in diabetes. Europ J Pharmacology 2004. 490:187-197.
115. Li ZG, Zhang W, Sima AA. Alzheimer-like changes in rat models of spontaneous diabetes. Diabetes 2007. 56:1817-1824.
116. Biessels GJ, Deary IJ, Ryan CM. Cognition and diabetes: a life-span perspective. Lancet Neurol 2008. 7:184-190.
117. Rexed B. Contributions to the knowledge of the postnatal development of the peripheral nervous system in man. Acto Psych Neurol 1944. Suppl. 33.
118. Jacobson M. Developmental Neurobiology. 2nd ed., Plenum Publ., New York, 1978.
119. Sima AA. Studies on fiber size in developing sciatic nerve and spinal roots in normal, undernourished and rehabilitated rats. Acta Physiol Scand 1974. Suppl. 406.
120. Harjutsalo V, Sjöberg L, Tuomiletho J. Time trends in the incidence of type 1 diabetes in Finnish children: a cohort study. Lancet 2008. 371:1777-1782.
121. Larsson HE, Hansson G, Carlsson A, Ceder-Wall E, Jonsson B, Jönsson B, Larsson K, Lynch K, Neidernd J, Lernmark A, Ivarsson SA. DiPiS Study Group: Children developing type 1 diabetes before 6 years of age have increased linear growth independent of HLA genotypes. Diabetologia 2008. 51:1623-1630.
122. Kumar P, Krishna P, Reddy SC, Gurappa M, Aravind SR, Munichoodappa C. Incidence of type 1 diabetes mellitus and associated complications among children and young adults: results from Karnataka Diabetes Registry 1995-2008. J Indian Med Assoc 2008. 106:708-711.]
123. Hills CE, Brunskill NJ. C-peptide and its intracellular signaling. Rev Diabet Stud 2009. This issue.